Johnson & Johnson Reports Strong Q2 Results and Raises Full-Year Guidance
Johnson & Johnson reported second-quarter results that exceeded expectations with strong pharmaceutical sales driving growth. The company raised its full-year guidance for both revenue and adjusted earnings per share, citing performance from key products like Tremfya and Darzalex.
Tickers: $JNJ
Topics: earnings guidance update pharmaceuticals